Dr. Osborne Discusses the Future of Treatment in HER2+ Breast Cancer

C. Kent Osborne, MD
Published: Thursday, Mar 16, 2017



C. Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the death of chemotherapy and rise of targeted agents in the treatment of patients with HER2-positive breast cancer.

The era of chemotherapy in HER2-positive breast cancer has ended, says Osborne, as genomic medicine that targets specific abnormalities within tumors is showing great effect.

According to Osborne, targeting the driver and alternate escape pathways of these tumors is next on the agenda for these agents.

<<< View more from the St. Gallen's Breast Cancer Conference


C. Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the death of chemotherapy and rise of targeted agents in the treatment of patients with HER2-positive breast cancer.

The era of chemotherapy in HER2-positive breast cancer has ended, says Osborne, as genomic medicine that targets specific abnormalities within tumors is showing great effect.

According to Osborne, targeting the driver and alternate escape pathways of these tumors is next on the agenda for these agents.

<<< View more from the St. Gallen's Breast Cancer Conference



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x